Compare NBIX & JHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | JHX |
|---|---|---|
| Founded | 1992 | 1888 |
| Country | United States | Ireland |
| Employees | N/A | 5860 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Building Materials |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 11.4B |
| IPO Year | 1996 | N/A |
| Metric | NBIX | JHX |
|---|---|---|
| Price | $163.88 | $22.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 22 | 9 |
| Target Price | ★ $180.91 | $27.83 |
| AVG Volume (30 Days) | 1.1M | ★ 7.2M |
| Earning Date | 05-05-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $161,626,000.00 | N/A |
| Revenue This Year | $24.73 | $26.06 |
| Revenue Next Year | $13.14 | $14.50 |
| P/E Ratio | ★ $87.58 | $122.05 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $122.14 | $16.46 |
| 52 Week High | $169.57 | $29.83 |
| Indicator | NBIX | JHX |
|---|---|---|
| Relative Strength Index (RSI) | 65.15 | 56.07 |
| Support Level | $134.92 | $19.16 |
| Resistance Level | N/A | $22.71 |
| Average True Range (ATR) | 4.51 | 0.92 |
| MACD | 0.13 | 0.21 |
| Stochastic Oscillator | 67.18 | 75.22 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
James Hardie is a manufacturer of fiber cement-based building products, selling primarily to the residential construction industry. North America is the primary geography, generating about 80% of group earnings. Here, it is the largest manufacturer of fiber cement, which is mainly used for exterior siding on houses. Following the Azek acquisition in 2025, it also produces wooden composite decking materials, siding trims, and accessories for outdoor areas including stair and deck railing. Businesses in Australia, New Zealand, and Europe, make up the rest of earnings.